Chipotle Mexican Grill, Inc. (NYSE:CMG) [Trend Analysis] knocking active thrust in leading trading session, shares an increase of 2.54% to 392.07 with around 1.37 Million shares have changed hands in this session. Chipotle Mexican Grill Inc. (CMG) hired Paul Cappuccio, Robin Hickenlooper, Ali Namvar and Matthew Paull as new members to its Board of Directors, effective December 14.
The new Directors will serve an initial term through Chipotle’s 2017 Annual Meeting of Shareholders, and the Board of Directors currently consists of twelve members.In connection with the appointments, Chipotle and Pershing Square have agreed to various provisions continuing at least until prior to the 2019 Annual Meeting of Shareholders. The stock is going forward its fifty-two week low with 11.08% and lagging behind from its 52-week high price with -32.14%.
Similar, the positive performance for the quarter recorded as -6.59% and for the year was -32.66%, while the YTD performance remained at -20.32%. CMG has Average True Range for 14 days of 12.23.
Dynavax Technologies Corporation (NASDAQ:DVAX) [Trend Analysis] retains strong position in active trade, as shares scoring 7.32% to $4.40 in active trade session, while looking at the shares volume, around 3.07 Million shares have changed hands in this session. The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Dynavax Technologies Corporation (DVAX) securities between March 10, 2014 and November 11, 2016.
According to the complaint, during the Class Period Dynavax made false and/or misleading statements and/or failed to disclose that: (i) the phase 3 HBV-23 trial for the Company’s lead vaccine product HEPLISAV-B was not designed in accordance with the U.S. Food and Drug Administration’s concerns and issues, as pointed out in a 2013 Complete Response Letter; (ii) Dynavax failed to provide sufficient information to the FDA in its Revised Biologics License Application for the drug; (iii) Dynavax’s resources will not be sufficient for the Company to advance the HEPLISAV-B program on its own; and (iv) as a result of the foregoing, the Company’s financial statements, as well as Defendants’ statements about Dynavax’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
The firm has institutional ownership of 83.50%, while insider ownership included 0.36%. DVAX attains analyst recommendation of 2.30 with week’s performance of -14.58%. Investors looking further ahead will note that the Price to next year’s EPS is 26.80%.